ImCheck to Present Updated Data from the EVICTION Trial at the 39th Annual Meeting of the Society for Immunotherapy of Cancer
05 nov. 2024 09h00 HE
|
ImCheck Therapeutics SAS
ImCheck to Present Updated Data from the EVICTION Trial at the 39th Annual Meeting of the Society for Immunotherapy of Cancer Marseille, France, November 5, 2024, 3 pm CET – ImCheck Therapeutics...
Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)
29 oct. 2024 10h00 HE
|
Longeveron
Longeveron presents clinical data for stem cell therapy in Alzheimer's disease. Findings offer potential mechanistic and clinical insights.
Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting
27 oct. 2024 15h10 HE
|
Longeveron
Longeveron reports positive long-term transplant-free survival (100% survival) data from a multi-year study in Hypoplastic Left Heart Syndrome (HLHS)
Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024
22 oct. 2024 08h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer...
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
15 oct. 2024 08h16 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage biopharmaceutical company leveraging its extensive...
Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024
15 oct. 2024 07h00 HE
|
Chemomab Therapeutics
Chemomab announces late-breaking oral presentation of CM-101 Phase 2 results in primary sclerosing cholangitis patients at 2024 AASLD The Liver Meeting
Longeveron® Lomecel-B™ Data in Alzheimer’s Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)
14 oct. 2024 09h05 HE
|
Longeveron
Longeveron Lomecel-B data in Alzheimer's disease selected for late breaking poster presentation at Clinical Trials on Alzheimer’s Disease Conf (CTAD24).
Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024 EORTC-NCI-AACR Symposium
10 oct. 2024 07h00 HE
|
Avacta Group
10 October 2024 Avacta Group plc(“Avacta” or “the Group” or “the Company”) Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024...
Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024 EORTC-NCI-AACR Symposium
10 oct. 2024 02h00 HE
|
Avacta Group
10 OctoberAvacta Group plc(“Avacta” or “the Group” or “the Company”)Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024 EORTC-NCI-AACR Symposium...
Avacta Reports Updated Phase 1 Clinical Data of AVA6000 at the European Society for Medical Oncology (ESMO) Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors
14 sept. 2024 03h00 HE
|
Avacta Group
This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act...